Results 181 to 190 of about 199,923 (254)

Frontotemporal dementia: Clinical aspects, genetics, and neuropathology of a family with a C9ORF72 expansion in Argentina

open access: yesBrain Pathology, EarlyView.
Immunohistochemistry for TDP‐43: (A)—Dentate gyrus; (B)—Temporal lobe. Abstract Frontotemporal dementia (FTD) is the second most common cause of early‐onset dementia, typically manifesting before the age of 65, with a mean onset at 58 years. FTD may encompass a spectrum of neurodegenerative disorders resulting from frontotemporal lobar degeneration ...
Karen Daniela Román   +13 more
wiley   +1 more source

Robustness of Working Memory to Prefrontal Cortex Microstimulation. [PDF]

open access: yesJ Neurosci
Soldado-Magraner J   +3 more
europepmc   +1 more source

Evidence of emerging transcriptome mediators of Alzheimer's disease in canine cognitive dysfunction

open access: yesBrain Pathology, EarlyView.
Canine cognitive dysfunction (CCD) may be a promising model of Alzheimer's disease (AD). To assess AD‐related molecular signatures in CCD, we generated transcriptome data on dog cortex and plasma extracellular vesicles (EVs). CCD‐related transcriptome changes were similar to those in aging/AD humans and were detectable in EVs from the same animals ...
Shelby C. Osburn   +7 more
wiley   +1 more source

Distinct regional patterns of synaptic vulnerability across hippocampal and parahippocampal subregions in Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Synaptic loss in Alzheimer's disease predominantly affects the entorhinal cortex and parahippocampal gyrus. Amyloid‐β and p‐tau pathology show global associations with synaptic density but are limited in specific subregions. Instead, axonal damage associates with synaptic loss locally and in interconnected subregions.
Maud M. A. Bouwman   +4 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander   +5 more
wiley   +1 more source

Ventromedial prefrontal cortex lesions disrupt learning to reward others. [PDF]

open access: yesBrain
Gueguen M   +7 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy